Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT05160480

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
9 (estimated)
Sponsor
University of California, Davis · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTotal-body PET imagingTotal-body PET imaging at different timepoints

Timeline

Start date
2024-06-07
Primary completion
2026-09-01
Completion
2026-09-01
First posted
2021-12-16
Last updated
2026-03-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05160480. Inclusion in this directory is not an endorsement.

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG (NCT05160480) · Clinical Trials Directory